Europe
Secarna provided a platform for discussion and information on antisense therapeutics with highly regarded experts from industry and academia
Manchester-based technology platform createsinnovative solution fordata curation in biomedicine
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market
A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry.
New Maetrics whitepaper highlights the compliance changes to CERs in light of the new EU Medical Device Regulations and how to navigate them
Bedfont Scientific Ltd. launches their new and improved FeNO monitor exclusively at the world’s largest European Respiratory Society Congress with a competition to win one.
Days after selling future royalty streams for two Sanofi diabetes drugs for $205 million, Denmark-based Zealand Pharma announced its Phase III trial for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints that sets up potential regulatory approval.
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), basically a rejection, to Netherlands-based Pharming Group for its supplemental Biologics License Application (sBLA) for Ruconest.
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
PRESS RELEASES